Wells Fargo downgraded Blueprint Medicines (BPMC) to Equal Weight from Overweight with a price target of $129, down from $143. The firm cites the pending takeover by Sanofi (SNY) for the downgrade.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BPMC:
- Blueprint Medicines announces data reinforcing sustained efficacy of AYVAKIT
- Blueprint Medicines price target raised to $129 from $88 at UBS
- Blueprint Medicines price target raised to $129 from $102 at Morgan Stanley
- Hold Rating on Blueprint Medicines Amid Sanofi Acquisition and Market Uncertainties
- Apple downgraded, Snowflake upgraded: Wall Street’s top analyst calls